Probenecid
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic gouty arthritis and hyperuricaemia — uricosuric therapy to reduce serum urate and prevent gout attacks | Adults | Long-term urate-lowering monotherapy or adjunct | FDA Approved |
| Adjunct to penicillin / cephalosporin therapy — to elevate and prolong antibiotic plasma levels by inhibiting renal tubular secretion | Adults and children ≥2 years | Antibiotic adjunct | FDA Approved |
Probenecid was first approved by the FDA in 1951 and remains one of the oldest urate-lowering therapies available. It acts as a competitive inhibitor of organic anion transport at the proximal renal tubule, blocking uric acid reabsorption and promoting its urinary excretion. The 2020 ACR guideline conditionally recommends probenecid as an alternative urate-lowering therapy when xanthine oxidase inhibitors are contraindicated, not tolerated, or insufficient as monotherapy. Probenecid requires adequate renal function (generally CrCl ≥50 mL/min) and is ineffective as a uricosuric at CrCl <30 mL/min. Separately, probenecid has a well-established role in prolonging penicillin and cephalosporin serum levels by inhibiting their renal tubular secretion.
Cidofovir nephroprotection — probenecid is co-administered with IV cidofovir to reduce nephrotoxicity by inhibiting active tubular secretion of cidofovir. Evidence: Moderate (standard of care per cidofovir PI).
Adjunct to other beta-lactam antibiotics — used to prolong serum levels of ampicillin, nafcillin, and other beta-lactams in select clinical scenarios (e.g., gonorrhoea treatment regimens). Evidence: Moderate (historical clinical use; CDC guidelines).
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Chronic gout — urate-lowering therapy | 250 mg BID for 1 week | 500 mg BID | 2 g/day (in divided doses) | Increase by 500 mg every 4 weeks if SUA not at target; titrate to SUA <6 mg/dL Do not start during an acute gout attack |
| Gout with combination XOI therapy | 250 mg BID | 500 mg BID (adjunct to allopurinol) | 2 g/day | May be added to XOI for patients not reaching SUA target on XOI alone ACR 2020 conditionally recommends combination over switching |
| Antibiotic adjunct (adults) | 500 mg QID (2 g/day) | 500 mg QID | 2 g/day | Administer with the antibiotic to prolong its serum levels 2–4-fold elevation of penicillin levels demonstrated |
| Antibiotic adjunct — paediatric (≥2 yr, <50 kg) | 25 mg/kg once | 40 mg/kg/day divided q6h | 500 mg/dose | For children ≥50 kg, use adult dosing Not recommended in children <2 years |
When starting probenecid for gout, urinary uric acid excretion increases substantially, creating risk for uric acid nephrolithiasis. Counsel patients to drink at least 2–3 litres (10–12 glasses) of fluid daily. Consider alkalinising the urine with sodium bicarbonate (3–7.5 g/day) or potassium citrate (7.5 g/day) to maintain urine pH ≥6.0, which increases urate solubility and reduces stone formation risk. This is especially important in the first weeks of therapy.
Probenecid is ineffective as a uricosuric agent in patients with significantly impaired renal function. It requires adequate glomerular filtration and tubular function to promote uric acid excretion. Most guidelines consider CrCl ≥50 mL/min the threshold for meaningful efficacy, and it is essentially ineffective at CrCl <30 mL/min. Assess renal function before initiating and periodically during therapy.
Pharmacology
Mechanism of Action
Probenecid is a sulfonamide-derivative organic acid that acts as a competitive inhibitor of the organic anion transporter (OAT) system in the proximal renal tubule. At therapeutic doses, it inhibits the reabsorption of uric acid at the OAT (primarily URAT1/SLC22A12), resulting in increased urinary excretion of uric acid and decreased serum urate levels. This uricosuric effect reduces the miscible urate pool, retards crystal deposition, and over time promotes resorption of existing urate deposits in tissues and joints.
Probenecid also inhibits the tubular secretion of many organic anions, including penicillins, cephalosporins, and other anionic drugs, via OAT1 and OAT3. This property is exploited therapeutically to prolong antibiotic plasma levels. Additionally, probenecid inhibits pannexin-1 channels, which may contribute anti-inflammatory effects by reducing inflammasome activation and IL-1β release, though this mechanism is not part of the approved indication.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Essentially complete oral absorption; Tmax 2–4 h; Cmax ~35 µg/mL (500 mg), ~70 µg/mL (1 g), ~150 µg/mL (2 g) | Rapid and reliable oral absorption; may be taken with food or antacids to reduce GI upset |
| Distribution | Protein binding 75–91% (albumin; dose-dependent); CSF concentrations ~2% of plasma; crosses placenta | High protein binding limits free drug and CNS penetration; minimal dialyzability |
| Metabolism | Hepatic: major metabolite is probenecid monoacyl glucuronide (~16–33% of dose); CYP-mediated alkyl side-chain oxidation produces 3 phase I metabolites (each <10% of dose); N-depropylation also occurs | Nonlinear (saturable) elimination at therapeutic doses; dose-dependent half-life reflects capacity-limited glucuronidation |
| Elimination | t½ 4–12 h (dose-dependent; longer at higher doses); ~5–11% excreted unchanged in urine (pH-dependent); renal clearance of parent drug 0.6–0.8 mL/min; metabolites excreted renally | Alkalinisation of urine decreases probenecid reabsorption but does not appreciably reduce its efficacy |
Side Effects
Probenecid was approved in 1951, before modern controlled trial adverse-reaction reporting standards. The PI lists adverse reactions by organ system without incidence percentages. The frequency estimates below are drawn from decades of clinical experience and published literature rather than from pivotal RCT data.
| Adverse Effect | Estimated Frequency | Clinical Note |
|---|---|---|
| GI upset (nausea, vomiting, anorexia) | Common (~5–10%) | Most frequent complaint; mitigated by taking with food or antacids; dose-related |
| Acute gout flares | Common (early therapy) | Due to urate mobilisation at therapy initiation; concurrent colchicine or NSAID prophylaxis recommended for ≥6 months |
| Headache | Common | Usually mild and self-limiting |
| Dizziness | Common | Counsel about driving/operating machinery |
| Urinary frequency | Common | Expected pharmacological effect from increased uric acid excretion combined with high fluid intake |
| Flushing | Uncommon | Transient; benign |
| Sore gums | Uncommon | Listed in PI; mechanism unclear |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Uric acid nephrolithiasis | Uncommon but clinically significant | First weeks to months of therapy | Ensure high fluid intake (≥2 L/day); alkalinise urine (pH ≥6.0); may need to reduce dose or discontinue |
| Nephrotic syndrome | Rare | Variable | Discontinue; nephrology referral; evaluate for alternative causes |
| Aplastic anaemia | Very rare | Variable | Discontinue immediately; urgent haematology referral; supportive care |
| Hemolytic anaemia | Very rare (may relate to G6PD deficiency) | Variable | Discontinue; check G6PD status; transfuse if needed |
| Hepatic necrosis | Extremely rare (single case report in literature) | Days to weeks (hypersensitivity-mediated) | Permanent discontinuation; never rechallenge; supportive care |
| Anaphylaxis / severe hypersensitivity | Rare | Any time | Discontinue permanently; treat per anaphylaxis protocol |
Uric acid nephrolithiasis is the most clinically important adverse effect to prevent. It is most likely in the early weeks of therapy when urinary uric acid excretion is highest, particularly in patients with pre-existing acidic urine or concentrated urine. Ensure patients maintain a liberal fluid intake of at least 2–3 litres per day and consider urine alkalinisation. Probenecid should not be initiated in patients with a history of uric acid kidney stones unless measures to prevent recurrence are in place.
Drug Interactions
Probenecid is a potent inhibitor of organic anion transporters (OAT1, OAT3, URAT1) and OATP1B1/1B3. This transporter inhibition is the basis of its uricosuric action but also produces extensive drug interactions by reducing the renal or hepatic clearance of many anionic drugs. Probenecid has one of the broadest drug interaction profiles of any gout therapy.
Monitoring
- Serum Uric AcidBaseline; at each dose change; then q3–6 months
RoutineTarget <6 mg/dL (or <5 mg/dL for severe tophaceous gout per ACR 2020). Guides dose titration. - Renal FunctionBaseline; periodically
RoutineCrCl or eGFR. Probenecid is ineffective if CrCl <30 mL/min and less effective at CrCl <50 mL/min. Reassess if renal function declines. - 24-Hour Urine Uric AcidBaseline (before starting)
RoutinePatients who are uric acid over-excretors (>800 mg/day on regular diet) are at higher risk for nephrolithiasis and may not be ideal candidates for uricosuric therapy. - Urine pHDuring initial therapy
Trigger-basedTarget urine pH ≥6.0 to increase uric acid solubility and reduce stone risk. Alkalinise with sodium bicarbonate or potassium citrate if needed. - Fluid IntakeOngoing counselling
RoutineEnsure at least 2–3 litres (10–12 glasses) of fluid daily to maintain dilute urine and prevent stone formation. - CBCBaseline; periodically
Trigger-basedVery rare haematologic effects (aplastic anaemia, leukopenia, haemolytic anaemia) listed in PI. Check if unexplained bruising, bleeding, or infection develops. - Drug Interaction ReviewAt initiation and each prescription change
Trigger-basedExtensive transporter-mediated interactions. Confirm no salicylate use. Review all concomitant medications for OAT-mediated interactions.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to probenecid — severe allergic reactions and anaphylaxis have been reported, particularly upon re-administration after prior use.
- Known blood dyscrasias — risk of exacerbating haematologic disorders.
- Uric acid kidney stones — probenecid increases urinary uric acid excretion and will worsen nephrolithiasis risk.
- Children under 2 years of age.
- Concomitant salicylate use — salicylates in any dose antagonise the uricosuric effect.
- Acute gout attack — do not initiate during an acute flare; however, if already on probenecid when a flare occurs, continue the drug and treat the flare separately.
Relative Contraindications (Specialist Input Recommended)
- CrCl <50 mL/min — diminished efficacy; consider switching to a xanthine oxidase inhibitor.
- History of nephrolithiasis (any type) — increased stone-forming risk from elevated urinary uric acid.
- Uric acid over-excretors (>800 mg/day) — already at high baseline stone risk; uricosurics further increase this.
Use with Caution
- Peptic ulcer disease — GI irritation may worsen symptoms.
- Sulfonamide allergy — probenecid is a sulfonamide derivative; cross-reactivity is possible though uncommon.
- Pregnancy — crosses placenta; limited human safety data.
- Lactation — distribution into human milk expected based on physicochemical properties; safety data lacking.
- G6PD deficiency — rare haemolytic anaemia reported in PI, possibly related to G6PD deficiency.
Patient Counselling
Purpose of Therapy
Probenecid helps your body get rid of excess uric acid through the kidneys. By lowering uric acid levels in the blood, it prevents gout attacks and allows existing uric acid crystal deposits to dissolve over time. It is a long-term preventive medicine — it does not treat a gout attack that is already happening.
How to Take
Take probenecid twice daily with food to minimise stomach upset. Your doctor will usually start with a lower dose and increase it gradually over several weeks based on blood test results. Do not stop taking probenecid without consulting your doctor, even if you feel well.
Sources
- Probenecid Tablets USP 500 mg Prescribing Information. Rising Pharma Holdings, Inc. DailyMedCurrent FDA-approved PI listing adverse reactions, contraindications, dosing, and drug interactions for probenecid.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for management of gout. Arthritis Care Res. 2020;72(6):744–760. doi:10.1002/acr.24180Current ACR guideline conditionally recommending probenecid as alternative ULT when XOI is contraindicated/not tolerated; supports combination ULT.
- Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–1446. doi:10.1002/acr.21772Prior ACR guideline providing detailed probenecid dosing and positioning; recommends uricosurics as alternative first-line in appropriate patients.
- Cunningham RF, Israeli ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981;6(2):135–151. doi:10.2165/00003088-198106020-00004Comprehensive PK review: complete oral absorption, t½ 4–12 h (dose-dependent), extensive hepatic metabolism, renal metabolite excretion.
- Vree TB, van Ewijk-Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity-limited renal glucuronidation of probenecid by humans. Pharm Weekbl Sci. 1992;14(5):325–331. doi:10.1007/BF01977622Demonstrated dose-dependent PK: t½ 3–6 h (250–1500 mg), protein binding 91%, saturable renal glucuronidation at therapeutic doses.
- Selen A, Amidon GL, Welling PG. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci. 1982;71(11):1238–1242. doi:10.1002/jps.2600711114PK study demonstrating dose-proportional Cmax, mean t½ of 4.2 h (500 mg) to 8.5 h (2 g), suggesting saturable elimination.
- Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447–452. doi:10.1038/nature742Identified URAT1 (SLC22A12) as the molecular target for uricosuric agents including probenecid; established the mechanism of renal urate reabsorption inhibition.
- Silverman W, Locovei S, Dahl G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol. 2008;295(3):C761–C767. doi:10.1152/ajpcell.00227.2008Original demonstration that probenecid specifically inhibits pannexin-1 channels without affecting connexin channels; established the mechanism underlying potential anti-inflammatory effects.
- Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349(17):1647–1655. doi:10.1056/NEJMcp030733Landmark review of gout management positioning probenecid within the urate-lowering armamentarium; discusses indications, limitations, and monitoring.
- Reynolds ES, Schlant RC, Gonick HC, Dammin GJ. Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. N Engl J Med. 1957;256(12):592–596. doi:10.1056/NEJM195703282561302Only published case of fatal hepatic necrosis from probenecid hypersensitivity; underscores that rechallenge after hypersensitivity reaction must be avoided.
- Probenecid. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; Updated July 10, 2020. NCBIComprehensive review of probenecid hepatotoxicity: extremely rare; single case of fatal hypersensitivity-mediated hepatic necrosis; no cases of chronic liver injury.
- Reinders MK, Jansen TL. Management of hyperuricemia in gout: focus on febuxostat. Clin Interv Aging. 2010;5:7–18. doi:10.2147/CIA.S4873Reviews positioning of uricosuric agents including probenecid relative to XOI therapy; discusses renal function requirements and combination strategies.